FATE EBITDA | FATE THERAPEUTICS INC

FATE THERAPEUTICS INC (FATE) EBITDA

2026-06-30: Basis Reported; EBITDA -$28.35M*; Operating income -$31.13M; Depreciation and amortization $2.78M*.
2026-03-31: Basis Reported; EBITDA -$30.08M; Operating income (m); Depreciation and amortization (m).
2025-12-31: Basis Reported; EBITDA -$31.66M; Operating income (m); Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA -$31.51M*; Operating income -$34.73M; Depreciation and amortization $3.23M*.

Complete source-backed ebitda history.

Available history: 2011-12-31 to 2026-03-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	-$28.35M*	-$31.13M	$2.78M*	$2.08M	-1361.86%*	$80.00K*	-$23.40M	(m)	$24.39M	(m)	(m)
2026-03-31	Reported	-$30.08M	(m)	(m)	(m)	-2315.78%	$239.00K	-$30.82M	(m)	$24.70M	(m)	(m)
2025-12-31	Reported	-$31.66M	(m)	(m)	(m)	-2312.49%	(m)	(m)	(m)	(m)	(m)	(m)
2025-09-30	Reported	-$31.51M*	-$34.73M	$3.23M*	$1.74M	-1809.76%*	$2.20M*	-$24.37M*	(m)	$25.84M	(m)	(m)
2025-06-30	Reported	-$33.69M*	-$36.97M	$3.28M*	$1.91M	-1766.65%*	$1.36M*	-$24.59M*	(m)	$27.43M	(m)	(m)
2025-03-31	Reported	-$37.95M	(m)	(m)	(m)	-2329.47%	$1.20M	-$33.81M	(m)	$29.14M	(m)	(m)
2024-12-31	Reported	-$56.94M	(m)	(m)	(m)	-3061.02%	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	-$47.77M*	-$52.38M	$4.61M*	$3.07M	-1554.00%*	$495.00K*	-$29.42M*	(m)	$34.65M	(m)	(m)
2024-06-30	Reported	-$40.36M*	-$45.08M	$4.72M*	$6.77M	-596.01%*	$51.00K*	-$32.31M*	(m)	$34.60M	(m)	(m)
2024-03-31	Reported	-$46.25M	(m)	(m)	(m)	-2402.44%	$86.00K	-$33.35M	(m)	$32.14M	(m)	(m)
2023-12-31	Reported	-$43.19M	(m)	(m)	(m)	-2576.97%	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	-$46.54M*	-$51.28M	$4.74M*	$1.94M	-2393.98%*	$565.00K*	-$38.27M*	(m)	$34.27M	(m)	(m)
2023-06-30	Reported	-$58.10M*	-$62.56M	$4.47M*	$933.00K	-6227.12%*	$2.20M*	-$28.49M*	(m)	$40.88M	(m)	(m)
2023-03-31	Reported	-$24.4M	(m)	(m)	(m)	-41.37%	$3.21M	-$28.86M	(m)	$65.63M	(m)	(m)
2022-12-31	Reported	-$59.58M	(m)	(m)	(m)	-134.32%	(m)	(m)	(m)	(m)	(m)	(m)
2022-09-30	Reported	-$83.20M*	-$86.39M	$3.19M*	$14.98M	-555.36%*	$8.68M*	-$55.05M*	(m)	$79.82M	(m)	(m)
2022-06-30	Reported	-$80.15M*	-$83.11M	$2.96M*	$18.55M	-432.08%*	$10.13M*	-$53.16M*	(m)	$81.31M	(m)	(m)
2022-03-31	Reported	-$71.71M	(m)	(m)	(m)	-389.41%	$10.08M	-$64.61M	(m)	$72.14M	(m)	(m)
2021-12-31	Reported	-$67.18M	(m)	(m)	(m)	-393.56%	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Reported	-$53.10M*	-$54.62M	$1.52M*	$14.22M	-373.31%*	$14.73M*	-$33.38M*	(m)	$53.13M	(m)	(m)
2021-06-30	Reported	-$45.61M*	-$46.78M	$1.17M*	$13.41M	-340.09%*	$13.62M*	-$32.11M*	(m)	$48.02M	(m)	(m)
2021-03-31	Reported	-$45.25M	(m)	(m)	(m)	-406.13%	$3.98M	-$27.10M	(m)	$44.85M	(m)	(m)
2020-12-31	Reported	-$32.54M	(m)	(m)	(m)	-204.69%	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Reported	-$30.71M*	-$31.49M	$773.00K*	$7.56M	-406.38%*	$954.00K*	-$30.73M*	(m)	$30.69M	(m)	(m)
2020-06-30	Reported	-$27.96M*	-$28.71M	$748.00K*	$5.46M	-511.60%*	$636.00K*	$38.84M*	(m)	$26.67M	(m)	(m)
2020-03-31	Reported	-$33.79M	(m)	(m)	(m)	-1343.42%	$1.07M	-$26.67M	(m)	$29.28M	(m)	(m)
2019-12-31	Reported	-$28.46M	(m)	(m)	(m)	-1015.52%	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Reported	-$26.53M*	-$27.12M	$587.00K*	$2.43M	-1092.30%*	$1.26M*	-$19.84M*	(m)	$23.20M	(m)	(m)
2019-06-30	Reported	-$23.54M*	-$24.08M	$543.00K*	$2.82M	-835.68%*	$1.79M*	-$20.31M*	(m)	$21.63M	(m)	(m)
2019-03-31	Reported	-$20.01M	(m)	(m)	(m)	-760.11%	$1.75M	-$17.49M	(m)	$17.73M	(m)	(m)
2018-12-31	Reported	-$16.41M	(m)	(m)	(m)	-988.20%	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Reported	-$16.38M*	-$16.69M	$310.00K*	$1.03M	-1596.69%*	$724.00K*	-$3.56M*	(m)	$13.64M	(m)	(m)
2018-06-30	Reported	-$19.32M*	-$19.61M	$281.00K*	$1.03M	-1881.60%*	$278.00K*	-$11.52M*	(m)	$16.82M	(m)	(m)
2018-03-31	Reported	-$13.77M	(m)	(m)	(m)	-1341.91%	$184.00K	-$12.55M	(m)	$11.48M	(m)	(m)
2017-12-31	Reported	-$11.95M	(m)	(m)	(m)	-1163.97%	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Reported	-$10.10M*	-$10.34M	$244.00K*	$1.03M	-984.02%*	$362.00K*	-$9.77M*	(m)	$8.58M	(m)	(m)
2017-06-30	Reported	-$9.34M*	-$9.57M	$231.00K*	$1.03M	-910.23%*	$411.00K*	(m)	(m)	$7.93M	(m)	(m)
2017-03-31	Reported	-$9.77M	(m)	(m)	(m)	(m)	$155.00K	(m)	(m)	$7.97M	(m)	(m)
2016-12-31	Reported	-$7.45M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-09-30	Reported	-$8.17M*	-$8.39M	$218.00K*	(m)	(m)	$33.00K*	(m)	(m)	$6.80M	(m)	(m)
2016-06-30	Reported	-$7.77M*	-$8.00M	$233.00K*	(m)	(m)	$206.00K*	(m)	(m)	$6.78M	(m)	(m)
2016-03-31	Reported	-$7.69M	(m)	(m)	(m)	(m)	$178.00K	(m)	(m)	$6.64M	(m)	(m)
2015-12-31	Reported	-$6.7M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-09-30	Reported	-$6.14M*	-$6.33M	$187.00K*	(m)	(m)	$655.00K*	(m)	(m)	$5.00M	(m)	(m)
2015-06-30	Reported	-$7.06M*	-$7.22M	$162.00K*	(m)	(m)	$213.00K*	(m)	(m)	$4.86M	(m)	(m)
2015-03-31	Reported	-$7.2M	(m)	(m)	(m)	(m)	$452.00K	(m)	(m)	$4.57M	(m)	(m)
2014-12-31	Reported	-$5.82M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-09-30	Reported	-$5.87M*	-$5.98M	$115.00K*	(m)	(m)	$187.00K*	(m)	(m)	$4.08M	(m)	(m)
2014-06-30	Reported	-$5.91M*	-$6.04M	$133.00K*	(m)	(m)	$26.00K*	(m)	(m)	$3.97M	(m)	(m)
2014-03-31	Reported	-$6.81M	(m)	(m)	(m)	(m)	$398.00K	(m)	(m)	$4.52M	(m)	(m)
2013-12-31	Reported	-$4.77M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2013-09-30	Reported	-$5.01M*	-$5.15M	$140.00K*	(m)	(m)	$23.00K*	(m)	(m)	$3.38M	(m)	(m)
2013-06-30	Reported	-$4.12M*	-$4.27M	$145.00K*	(m)	(m)	$64.00K*	(m)	(m)	$3.07M	(m)	(m)
2013-03-31	Reported	-$3.2M	(m)	(m)	(m)	-677.75%	$7.00K	(m)	(m)	$2.53M	(m)	(m)
2012-12-31	Reported	-$3.88M	(m)	(m)	(m)	-604.04%	(m)	(m)	(m)	(m)	(m)	(m)
2012-09-30	Reported	(m)	-$3.65M	(m)	(m)	(m)	(m)	(m)	(m)	$3.31M	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	-$134.8M	(m)	(m)	(m)	-2028.33%	$5.95M	-$106.08M	(m)	$107.83M	(m)	$2.00K
2024-12-31	Reported	-$191.31M	(m)	(m)	(m)	-1403.52%	$730.00K	-$122.87M	(m)	$135.00M	(m)	$0.00
2023-12-31	Reported	-$172.23M	(m)	(m)	(m)	-271.09%	$6.15M	-$132.26M	(m)	$172.60M	(m)	$0.00
2022-12-31	Reported	-$294.63M	(m)	(m)	(m)	-305.95%	$35.57M	-$248.21M	(m)	$320.45M	(m)	$0.00
2021-12-31	Reported	-$211.14M	(m)	(m)	(m)	-378.08%	$50.70M	-$162.87M	(m)	$215.52M	(m)	$0.00
2020-12-31	Reported	-$125M	(m)	(m)	(m)	-397.65%	$4.93M	-$39.23M	(m)	$125.62M	(m)	$0.00
2019-12-31	Reported	-$98.53M	(m)	(m)	(m)	-922.60%	$7.39M	-$83.17M	(m)	$87.77M	(m)	$0.00
2018-12-31	Reported	-$65.89M	(m)	(m)	(m)	-1390.04%	$2.30M	-$38.65M	(m)	$56.02M	(m)	(m)
2017-12-31	Reported	-$41.15M	(m)	(m)	(m)	-1002.29%	$1.73M	-$36.82M	(m)	$34.36M	(m)	(m)
2016-12-31	Reported	-$31.08M	(m)	(m)	(m)	-706.09%	$457.00K	-$29.82M	(m)	$26.45M	(m)	(m)
2015-12-31	Reported	-$27.1M	(m)	(m)	(m)	-1114.56%	$1.50M	(m)	(m)	$19.86M	(m)	(m)
2014-12-31	Reported	-$24.41M	(m)	(m)	(m)	(m)	$882.00K	(m)	(m)	$16.43M	(m)	(m)
2013-12-31	Reported	-$17.1M	(m)	(m)	(m)	-1761.48%	$244.00K	(m)	(m)	$12.01M	(m)	(m)
2012-12-31	Reported	-$12.97M	(m)	(m)	(m)	-485.66%	$709.00K	(m)	(m)	$12.00M	(m)	(m)
2011-12-31	Reported	-$12.62M	(m)	(m)	(m)	-1078.72%	$2.00K	(m)	(m)	$9.86M	(m)	(m)

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Liminatus Pharma, Inc. (LIMN)	United States	$0.282B
Lexeo Therapeutics, Inc. (LXEO)	United States	$0.278B	-4.19
PALISADE BIO, INC. (PALI)	United States	$0.275B	-11.41
Invivyd, Inc. (IVVD)	United States	$0.270B	-2.42
Inhibikase Therapeutics, Inc. (IKT)	United States	$0.296B	-4.44
X4 Pharmaceuticals, Inc (XFOR)	United States	$0.297B	-4.99
SUTRO BIOPHARMA, INC. (STRO)	United States	$0.260B	-3.05
SAB Biotherapeutics, Inc. (SABS)	United States	$0.306B	-25.49
Century Therapeutics, Inc. (IPSC)	United States	$0.306B	-4.02
Lineage Cell Therapeutics, Inc. (LCTX)	United States	$0.241B	-10.35